Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/14/2012 | 06:55pm CEST

--FDA concludes safety review of MS drug Gilenya

--FDA advises against use in certain heart and stroke patients

--FDA says no clear link between Gilenya and cardiovascular deaths

(Updates with additional background on EMA review starting in seventh paragraph and information on experimental Biogen Idec MS drug.)

 
   By Jennifer Corbett Dooren 
   Of  
 

The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.

The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.

The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily.

As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear."

The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines.

Europe's drug regulator, the European Medicines Agency, last month requested stronger safety warnings for Gilenya after the agency concluded its review of the drug.

Gilenya is currently the only oral MS drug on the market but its sales prospects have been clouded by recent safety concerns. It was approved in the U.S. in 2010 and has been available in Europe since 2011.

The product is designed to treat patients with the relapsing form of MS, which is a progressive disease that involves damage to the nerves controlling muscles and vision.

The FDA is currently reviewing another oral MS drug from Biogen Idec Inc. (BIIB) called BG-12 that is designed to work through a different mechanism than Gilenya. Biogen Idec last week announced that the FDA accepted BG-12's new drug application for a standard 10-month review, which sets an agency decision deadline of about Dec. 28.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN -1.13% 263.02 Delayed Quote.-16.50%
NOVARTIS -1.55% 76.08 Delayed Quote.-6.21%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
04/20Generics group Alvogen puts Eastern European operations up for sale - sources
RE
04/20NOVARTIS : renews commitment to malaria elimination, investing USD 100 million t..
AQ
04/20AVEXIS : Novartis tender offer for AveXis commences
AQ
04/20AMGEN : Novartis presents first-of-its-kind evidence at AAN reinforcing robust a..
AQ
04/20NOVARTIS : Jay Bradner bemoans `redundant investment in the biotech sector` for ..
AQ
04/20NOVARTIS : Surface slips in first trading day
AQ
04/20NOVARTIS : New Novartis analyses at AAN show siponimod's efficacy on disability ..
GL
04/19NOVARTIS : Patent Issued for Brake System (USPTO 9939603)
AQ
04/19NOVARTIS : Patent Issued for Adjusting Laser Treatment in Response to Changes in..
AQ
04/19NOVARTIS : Sandoz signs agreement with Pear Therapeutics to develop and commerci..
AQ
More news
News from SeekingAlpha
04/20WALL STREET BREAKFAST, APRIL 20TH : Tough Trade Talk With China And Canada, Russ.. 
04/20YOUR DAILY PHARMA SCOOP : Adamas Update, Shire Bidding War, Novartis Results 
04/20WALL STREET BREAKFAST : Spring Meetings For IMF, World Bank 
04/19Novartis AG (NVS) Q1 2018 Results - Earnings Call Transcript 
04/19Novartis AG 2018 Q1 - Results - Earnings Call Slides 
Financials ($)
Sales 2018 52 423 M
EBIT 2018 12 838 M
Net income 2018 8 826 M
Debt 2018 14 696 M
Yield 2018 3,76%
P/E ratio 2018 16,54
P/E ratio 2019 19,35
EV / Sales 2018 4,35x
EV / Sales 2019 4,18x
Capitalization 213 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 93,0 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
Srikant Madhav Datar Independent Non-Executive Director
Andreas von Planta Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-6.21%213 465
JOHNSON & JOHNSON-8.59%342 627
PFIZER0.75%217 064
ROCHE HOLDING LTD.-12.17%193 713
MERCK AND COMPANY4.21%158 813
AMGEN0.70%117 021